
USD
$0.00
(0.00%
)At Close (As of Oct 23, 2025)
$222.69B
Market Cap
16.07
P/E Ratio
7.96
EPS
$139.33
52 Week High
$109.21
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $21B |
| Total Revenue | $42B |
| Cost Of Revenue | $21B |
| Costof Goods And Services Sold | $21B |
| Operating Income | $6.8B |
| Selling General And Administrative | $12B |
| Research And Development | $2.8B |
| Operating Expenses | $14B |
| Investment Income Net | - |
| Net Interest Income | -$215M |
| Interest Income | $344M |
| Interest Expense | $603M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $3.2B |
| Income Before Tax | $7B |
| Income Tax Expense | -$6.4B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $13B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $7.6B |
| Ebitda | $11B |
| Net Income | $13B |
| Field | Value (USD) |
|---|---|
| Total Assets | $81B |
| Total Current Assets | $24B |
| Cash And Cash Equivalents At Carrying Value | $7.6B |
| Cash And Short Term Investments | $7.6B |
| Inventory | $6.2B |
| Current Net Receivables | $6.9B |
| Total Non Current Assets | $58B |
| Property Plant Equipment | $12B |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $6.6B |
| Intangible Assets Excluding Goodwill | $6.6B |
| Goodwill | $23B |
| Investments | - |
| Long Term Investments | $886M |
| Short Term Investments | $351M |
| Other Current Assets | $2.6B |
| Other Non Current Assets | - |
| Total Liabilities | $34B |
| Total Current Liabilities | $14B |
| Current Accounts Payable | $4.2B |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $1.8B |
| Total Non Current Liabilities | $19B |
| Capital Lease Obligations | $896M |
| Long Term Debt | $13B |
| Current Long Term Debt | $1.5B |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $15B |
| Other Current Liabilities | $7.6B |
| Other Non Current Liabilities | $3.4B |
| Total Shareholder Equity | $48B |
| Treasury Stock | - |
| Retained Earnings | $47B |
| Common Stock | $25B |
| Common Stock Shares Outstanding | $1.7B |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $8.6B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $3.2B |
| Capital Expenditures | $2.2B |
| Change In Receivables | - |
| Change In Inventory | -$58M |
| Profit Loss | - |
| Cashflow From Investment | -$2.3B |
| Cashflow From Financing | -$5.4B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $3.8B |
| Dividend Payout Common Stock | $3.8B |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$1.3B |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $13B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $21B |
| Total Revenue | $42B |
| Cost Of Revenue | $21B |
| Costof Goods And Services Sold | $21B |
| Operating Income | $6.8B |
| Selling General And Administrative | $12B |
| Research And Development | $2.8B |
| Operating Expenses | $14B |
| Investment Income Net | - |
| Net Interest Income | -$215M |
| Interest Income | $344M |
| Interest Expense | $603M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $3.2B |
| Income Before Tax | $7B |
| Income Tax Expense | -$6.4B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $13B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $7.6B |
| Ebitda | $11B |
| Net Income | $13B |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-10-15 |
| Declaration Date | 2025-09-19 |
| Record Date | 2025-10-15 |
| Payment Date | 2025-11-17 |
| Amount | 0.59 |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Abbott Laboratories (ABT) is a prominent American multinational healthcare company based in Abbott Park, Illinois, with expertise across a diverse range of sectors, including medical devices, diagnostics, nutritional products, and branded generic medicines. Established in 1888, Abbott has demonstrated a strong commitment to innovation, enhancing health outcomes through cutting-edge technology and comprehensive healthcare solutions. The company's strategic decision to spin off its research-based pharmaceutical operations into AbbVie in 2013 has allowed it to focus on its core offerings while maintaining a legacy of excellence in healthcare. With a robust global presence, Abbott is well-positioned to capitalize on emerging market opportunities and address evolving healthcare needs.